Pα+ Psychedelic Bulletin #165: A Closer Look at a Buzzy Oral Ketamine for Depression Study; UN Weighs In on Psychedelics; Another CA Psychedelics Bill Fails Post published:June 28, 2024 Post category:Psychedelic Bulletin/Pα+
No NHS Coverage for Janssen’s Spravato: NICE Denies Re-Appraisal of Esketamine for TRD Post published:June 21, 2024 Post category:Analysis/News/Pα+
Pα+ Psychedelic Bulletin #164: Lykos Dominates News Cycle; EPIsoDE Trial Readout; EU Drug Report Discusses Psychedelics; DEA Should Improve RFRA Petition Process; Other News Post published:June 14, 2024 Post category:Psychedelic Bulletin/Pα+
Analysis: FDA Advisory Committee Snubs MDMA-Assisted Therapy for PTSD in Overwhelming “No” Vote Post published:June 11, 2024 Post category:Analysis/News/Pα+
ICER Panel Rejects MDMA-Assisted Therapy, Highlights Evidence Gaps and Study Flaws in 14-1 Vote Post published:May 31, 2024 Post category:Analysis/News/Pα+
Patients, Practitioners, Researchers and Public Submit Comments Ahead of FDA Advisory Committee on MDMA Post published:May 29, 2024 Post category:Analysis/Pα+
What to Expect: FDA Advisory Committee Set to Review MDMA-Assisted Therapy for PTSD Post published:May 27, 2024 Post category:Analysis/Pα+
Pα+ Psychedelic Patent Analysis: April 2024 Post published:May 24, 2024 Post category:Psychedelic Patent Analysis/Pα+
Pα+ Psychedelic Bulletin #163: Tempering Excitement Around Recent Raises; Compass Shares Cut of Open-Label PTSD Data; Other News Post published:May 17, 2024 Post category:Psychedelic Bulletin/Pα+
Breaking: AbbVie Inks Deal with Gilgamesh Pharmaceuticals Post published:May 13, 2024 Post category:Analysis/News/Pα+